HK1010139A1 - Encapsulated cells producing viral particles. - Google Patents

Encapsulated cells producing viral particles.

Info

Publication number
HK1010139A1
HK1010139A1 HK98110992A HK98110992A HK1010139A1 HK 1010139 A1 HK1010139 A1 HK 1010139A1 HK 98110992 A HK98110992 A HK 98110992A HK 98110992 A HK98110992 A HK 98110992A HK 1010139 A1 HK1010139 A1 HK 1010139A1
Authority
HK
Hong Kong
Prior art keywords
encapsulated cells
viral particles
cells producing
producing viral
genes
Prior art date
Application number
HK98110992A
Other languages
English (en)
Inventor
Robert Michael Saller
Walter H Gunzburg
Brian Salmons
Original Assignee
Bavarian Nordic As
Gsfforschungszentrum Fur Umwel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8097001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1010139(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic As, Gsfforschungszentrum Fur Umwel filed Critical Bavarian Nordic As
Publication of HK1010139A1 publication Critical patent/HK1010139A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/13011Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/13011Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
HK98110992A 1995-06-27 1998-09-26 Encapsulated cells producing viral particles. HK1010139A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK74095 1995-06-27
PCT/EP1996/002748 WO1997001357A1 (en) 1995-06-27 1996-06-24 Encapsulated cells producing viral particles

Publications (1)

Publication Number Publication Date
HK1010139A1 true HK1010139A1 (en) 1999-06-17

Family

ID=8097001

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98110992A HK1010139A1 (en) 1995-06-27 1998-09-26 Encapsulated cells producing viral particles.

Country Status (22)

Country Link
US (1) US6776985B1 (xx)
EP (1) EP0835137B1 (xx)
JP (2) JP4119952B2 (xx)
KR (1) KR100484883B1 (xx)
CN (1) CN1187095C (xx)
AT (1) ATE309000T1 (xx)
AU (1) AU708273B2 (xx)
CA (1) CA2222559A1 (xx)
CZ (1) CZ286979B6 (xx)
DE (1) DE69633180D1 (xx)
DK (1) DK0835137T3 (xx)
ES (1) ES2253754T3 (xx)
HK (1) HK1010139A1 (xx)
IL (1) IL122119A (xx)
NO (1) NO321427B1 (xx)
NZ (1) NZ312671A (xx)
PL (1) PL185338B1 (xx)
PT (1) PT835137E (xx)
RU (1) RU2187301C2 (xx)
SI (1) SI0835137T1 (xx)
UA (1) UA65525C2 (xx)
WO (1) WO1997001357A1 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5103996A (en) 1995-03-09 1996-10-02 Bavarian Nordic Research Institute A/S Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy
CA2222559A1 (en) 1995-06-27 1997-01-16 Bavarian Nordic Research Institute A/S Encapsulated cells producing viral particles
US6540995B1 (en) 1996-03-27 2003-04-01 Bavarian Nordic Research Institute Gmbh Encapsulated cells producing cytochrome P450
PL188323B1 (pl) 1996-03-27 2005-01-31 Bavarian Nordic As Kapsuła zawierająca komórki i jej zastosowanie oraz kompozycja i środek farmaceutyczny
CN1266362A (zh) 1998-05-05 2000-09-13 皇家菲利浦电子有限公司 包括具有刷毛区和齿间刷毛区的毛刷件的牙刷
EP2075254A1 (en) 2004-03-30 2009-07-01 NsGene A/S Therapeutic use of a growth factor, NsG33
EP1879622A2 (en) * 2005-05-03 2008-01-23 Veterinärmedizinische Universität Wien Permeable capsules
PL2231209T3 (pl) * 2007-12-20 2019-08-30 Ethicon, Incorporated Enkapsulowana tkanka nerkowa
KR101250925B1 (ko) * 2011-10-28 2013-04-04 한화케미칼 주식회사 캡슐 세포용 구조체
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
DE102016122317A1 (de) * 2015-11-24 2017-05-24 Glaxosmithkline Intellectual Property Development Limited Transientes transfektionsverfahren für retrovirale produktion
ES2939617T3 (es) * 2015-11-24 2023-04-25 Glaxosmithkline Ip Dev Ltd Líneas celulares estables para producción retroviral
CA3023473A1 (en) 2016-05-25 2017-11-30 Lonza Houston Inc. Methods for isolating adeno-associated virus using a polydiallyldialkylammonium salt
RU2688383C2 (ru) * 2017-07-10 2019-05-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Способ синтеза белка в культуре бактериальных клеток
CN110615667B (zh) * 2018-06-19 2022-02-15 华北理工大学 基于铁尾矿和碱渣的核壳结构陶粒及其制备方法
WO2022246174A2 (en) * 2021-05-21 2022-11-24 Bionaut Labs Ltd. System and method for localized therapeutic treatment
CN115820683B (zh) * 2022-09-28 2024-04-05 西南大学 家蚕Cyp9a20基因及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
DD160393A3 (de) * 1980-11-14 1983-07-27 Horst Dautzenberg Mikrokapseln und verfahren zu ihrer herstellung
US4686098A (en) * 1984-05-14 1987-08-11 Merck & Co., Inc. Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivo
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
EP0199362A3 (en) * 1985-04-26 1987-10-07 Massachusetts Institute Of Technology System and apparatus for delayed and pulsed release of biologically active substances
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
CA1335798C (en) 1988-05-17 1995-06-06 Sloan Kettering Institute For Cancer Research Retroviral vector
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE4021050A1 (de) * 1990-06-29 1992-01-02 Akad Wissenschaften Ddr Verfahren zur herstellung von mikrokapseln
CA2051288C (en) * 1990-09-14 2002-02-05 Robert L. Martuza Viral targeted destruction of neoplastic cells
JPH06500927A (ja) * 1990-12-13 1994-01-27 アメリカ合衆国 高力価の組換えウイルスベクターおよび遺伝子療法に用いられる形質導入標的細胞の持続的及び連続的生産
WO1994029437A1 (en) 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
ATE200517T1 (de) 1994-09-02 2001-04-15 Gsf Forschungszentrum Umwelt Nicht selbstinaktivierende retrovirale vektoren mit gezielter expression
CA2222559A1 (en) 1995-06-27 1997-01-16 Bavarian Nordic Research Institute A/S Encapsulated cells producing viral particles
DE69619683T2 (de) 1995-09-06 2002-09-26 Austrian Nordic Biotherapeutic Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv
PL188323B1 (pl) 1996-03-27 2005-01-31 Bavarian Nordic As Kapsuła zawierająca komórki i jej zastosowanie oraz kompozycja i środek farmaceutyczny

Also Published As

Publication number Publication date
SI0835137T1 (sl) 2006-04-30
IL122119A0 (en) 1998-04-05
ES2253754T3 (es) 2006-06-01
NO975813L (no) 1998-02-23
NO321427B1 (no) 2006-05-08
WO1997001357A1 (en) 1997-01-16
AU708273B2 (en) 1999-07-29
CN1189104A (zh) 1998-07-29
PL324289A1 (en) 1998-05-11
RU2187301C2 (ru) 2002-08-20
NO975813D0 (no) 1997-12-10
CZ286979B6 (en) 2000-08-16
JPH11508768A (ja) 1999-08-03
JP4848348B2 (ja) 2011-12-28
NZ312671A (en) 1999-10-28
EP0835137A1 (en) 1998-04-15
PT835137E (pt) 2004-12-31
CZ419597A3 (cs) 1998-03-18
JP2008101011A (ja) 2008-05-01
IL122119A (en) 2004-06-01
CN1187095C (zh) 2005-02-02
JP4119952B2 (ja) 2008-07-16
DE69633180D1 (de) 2004-09-23
DK0835137T3 (da) 2006-03-06
KR100484883B1 (ko) 2005-09-02
PL185338B1 (pl) 2003-04-30
CA2222559A1 (en) 1997-01-16
UA65525C2 (en) 2004-04-15
ATE309000T1 (de) 2005-11-15
KR19990028491A (ko) 1999-04-15
US6776985B1 (en) 2004-08-17
EP0835137B1 (en) 2005-11-09
AU6415496A (en) 1997-01-30

Similar Documents

Publication Publication Date Title
HK1010139A1 (en) Encapsulated cells producing viral particles.
CA2092195A1 (en) Retroviral packaging cell line
AU6871398A (en) Method for enhancing expression of a foreign or endogenous gene product in pla nts
CA2130454A1 (en) Production of viral resistant plants via introduction of untranslatable plus sense viral rna
CA2182303A1 (fr) Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire
KR970700771A (ko) 비-바이러스 벡터(Non-viral vector)
ZA968382B (en) Vector and method of use for nucleic acid delivery to non-dividing cells
GB9813540D0 (en) Chemical compounds
WO1996019568A3 (en) Stabilized ribozyme analogs
CA2154023A1 (en) Recombinant infectious non-segmented negative strand rna virus
WO1996013597A3 (en) Improved adenovirus and methods of use thereof
AU6933496A (en) Antagonists of the oncogenic activity of the MDM2 protein and their use in the treatment of cancers
AU5720498A (en) Chemical synthesis of nucleosides analogs and their incorporation into polynucleotides
PL336640A1 (en) Substituted 3,3-diamino-2- propenonitriles, their production and application
DK0843731T3 (da) Adenovirusvektorer til genterapi
AU5103996A (en) Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy
DE69619808D1 (de) Chimäre msp und daf proteine mit einem telloberflächenlokalisierendem domän
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
WO1996033282A3 (en) High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
ZA986336B (en) Medicaments comprising polyhydroxybutylpyrazines novel polyhydroxybutylpyrazines and their preparation
CA2331440A1 (en) Amphotropic retrovirus packaging cell line, process for its production and use thereof
WO1988004666A3 (en) Lung cytotoxic peptides
PT1173471E (pt) Análogos de pseudomicinas
AU1275095A (en) Antiviral composition of viral protein trans-dominant variants
WO2001018039A3 (en) INCREASED PRODUCTION OF INTERFERON-$g(a)

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110624